8月18日，沪深两融数据显示，伟思医疗获融资买入额0.47亿元，居两市第680位，当日融资偿还额0.43 亿元，净买入375.87万元。 来源：金融界 最近三个交易日，14日-18日，伟思医疗分别获融资买入0.36亿元、0.34亿元、0.47亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Weisi Medical, which closed at 55.51 yuan with a PE ratio of 46.87 times, indicating a strong market position within the medical device industry [1][2] - Weisi Medical's total market capitalization is reported at 5.316 billion yuan, ranking 84th in the medical device industry based on PE ratio, which has an average of 56.58 times and a median of 39.97 times [1][2] - The company specializes in the research, production, and sales of medical devices, with key products including magnetic stimulation, electrical stimulation, electrophysiology, consumables, and laser radiofrequency [1] Group 2 - For the first quarter of 2025, Weisi Medical reported a revenue of 95.9127 million yuan, reflecting a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, which is a significant year-on-year increase of 52.71% [1] - The gross profit margin for Weisi Medical stands at 66.65%, indicating strong profitability in its operations [1] - As of the first quarter of 2025, only one institution holds shares in Weisi Medical, with a total of 90,000 shares valued at 0.04 million yuan [1]

Core Viewpoint - Weisi Medical has shown significant growth in stock performance and financial results, indicating a strong position in the medical device industry, particularly in innovative technologies and market expansion efforts [1] Financial Performance - As of March 31, 2025, Weisi Medical achieved total operating revenue of 95.91 million, representing a year-on-year growth of 9.40% [1] - The company reported a net profit attributable to shareholders of 33.22 million, marking a substantial increase of 52.71% year-on-year [1] - The liquidity ratios are strong, with a current ratio of 7.579 and a quick ratio of 7.341, while the debt-to-asset ratio stands at a low 8.47% [1] Stock Performance - On August 15, the stock price of Weisi Medical increased by 1.82%, with a trading volume of 198 million and a turnover rate of 3.74% [1] - Over the past 10 trading days, the stock has accumulated a total increase of 22.0% [1] - The net outflow of main funds on the same day was 5.47 million, accounting for 2.76% of the trading volume, while large orders saw a net inflow of 3.34 million, representing 1.69% of the trading volume [1] Business Focus - Weisi Medical is primarily engaged in the research, development, production, and sales of medical devices, with a focus on innovative technologies such as electrical stimulation, magnetic stimulation, electrophysiology, rehabilitation robotics, and aesthetic energy sources [1] - The company aims to become a global leader in the magnetic stimulation field and a leading supplier in the rehabilitation and aesthetic sectors within China, while also exploring overseas markets and innovative models for TMS treatment of depression [1]

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 8月14日，沪深两融数据显示，伟思医疗获融资买入额0.36亿元，居两市第671位，当日融资偿还额0.48 亿元，净卖出1222.99万元。 最近三个交易日，12日-14日，伟思医疗分别获融资买入0.60亿元、0.54亿元、0.36亿元。 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Weisi Medical, which closed at 54.52 yuan with a decline of 2.64%, resulting in a rolling PE ratio of 46.03 times and a total market value of 5.221 billion yuan [1] - In comparison to the medical device industry, Weisi Medical's PE ratio is below the industry average of 55.76 times and the industry median of 39.14 times, ranking 82nd in the sector [1][2] - As of the first quarter of 2025, only one institution holds shares in Weisi Medical, with a total of 90,000 shares valued at 0.04 million yuan [1] Group 2 - Weisi Medical specializes in the research, production, and sales of medical devices, with key products including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency [1] - The latest financial results for the first quarter of 2025 show that the company achieved a revenue of 95.9127 million yuan, representing a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1]

金融界消息 截至2025年8月14日收盘，伟思医疗（688580）报收于54.52元，下跌2.64%，换手率4.9%， 成交量4.70万手，成交金额2.58亿元。 资金流向方面，今日主力资金净流出2692.66万元，占比成交额10.42%。其中，超大单净流出166.32万 元、占成交额0.64%，大单净流出2526.33万元、占成交额9.78%，中单净流出流入556.05万元、占成交 额2.15%，小单净流入2136.61万元、占成交额8.27%。 伟思医疗最新一期业绩显示，截至2025一季报，公司营业总收入9591.27万元、同比增长9.40%，归属净 利润3322.01万元，同比增长52.71%，扣非净利润3053.83万元，同比增长58.96%，流动比率7.579、速动 比率7.341、资产负债率8.47%。 天眼查商业履历信息显示，南京伟思医疗科技股份有限公司，成立于2001年，位于南京市，是一家以从 事医药制造业为主的企业。企业注册资本9577.1288万人民币，实缴资本5126万人民币。公司法定代表 人为王志愚。 通过天眼查大数据分析，南京伟思医疗科技股份有限公司共对外投资了11家企业，参与招投标 ...

Industry Overview - On August 14, the medical device industry experienced a decline of 2.45% with a net outflow of 1.74 billion yuan in principal funds [1] - Among the component stocks, 13 increased while 87 decreased [1] Major Fund Outflows - The companies with the highest net outflows of principal funds included: - Kehua Bio (29.96 million yuan) - Baolait (29.32 million yuan) - Shangrong Medical (28.74 million yuan) - Weisi Medical (26.93 million yuan) - ST Kelly (26.25 million yuan) [1] Notable Stock Performance - Key stocks with significant movements included: - Sainuo Medical: Latest price 30.43, up 3.05%, with a net inflow of 164 million yuan (7.25% of total) [1] - Botao Bio: Latest price 45.13, up 19.99%, with a net inflow of 543.74 thousand yuan (12.47% of total) [1] - Yuyue Medical: Latest price 35.67, down 0.17%, with a net inflow of 49.30 thousand yuan (12.91% of total) [1] - Kefu Medical: Latest price 40.58, up 6.99%, with a net inflow of 470.40 thousand yuan (14.3% of total) [1] - Huatai Medical: Latest price 290.99, down 2.03%, with a net inflow of 297.47 thousand yuan (9.99% of total) [1] - Aohua Endoscopy: Latest price 49.14, down 7.79%, with a net inflow of 2363.53 thousand yuan (10.09% of total) [1] - Meihua Medical: Latest price 20.94, up 3.05%, with a net inflow of 2316.72 thousand yuan (4.81% of total) [1] - Wanfu Bio: Latest price 24.28, down 0.92%, with a net inflow of 184.26 thousand yuan (5.48% of total) [1] - Zhijiang Bio: Latest price 25.24, up 4.87%, with a net inflow of 1420.31 thousand yuan (5.07% of total) [1] - Mairande: Latest price 51.64, up 1.06%, with a net inflow of 1335.64 thousand yuan (2.42% of total) [1]

Core Insights - On August 13, Weisi Medical's stock closed at 56.00 yuan, an increase of 0.14 yuan, representing a 0.25% rise [1] - The trading volume for the day was 48,657 hands, with a transaction amount of 270 million yuan, resulting in a turnover rate of 5.08% [1] - Weisi Medical operates in the medical device sector, focusing on the research, production, and sales of medical equipment, including rehabilitation medical devices and surgical instruments [1] Financial Performance - On August 13, the net outflow of main funds for Weisi Medical was 14.5931 million yuan, with a cumulative net outflow of 8.8830 million yuan over the past five days [1] - The overall performance of the medical device sector on that day was poor, with several related stocks experiencing declines [1]

通过天眼查大数据分析，南京伟思医疗科技股份有限公司共对外投资了11家企业，参与招投标项目1239 次，知识产权方面有商标信息173条，专利信息291条，此外企业还拥有行政许可166个。 金融界消息 截至2025年8月13日收盘，伟思医疗（688580）报收于56.0元，上涨0.25%，换手率5.08%， 成交量4.87万手，成交金额2.70亿元。 来源：金融界 资金流向方面，今日主力资金净流出1459.31万元，占比成交额5.4%。其中，超大单净流出387.66万 元、占成交额1.44%，大单净流出1071.65万元、占成交额3.97%，中单净流出流入939.16万元、占成交 额3.48%，小单净流入520.15万元、占成交额1.93%。 伟思医疗最新一期业绩显示，截至2025一季报，公司营业总收入9591.27万元、同比增长9.40%，归属净 利润3322.01万元，同比增长52.71%，扣非净利润3053.83万元，同比增长58.96%，流动比率7.579、速动 比率7.341、资产负债率8.47%。 天眼查商业履历信息显示，南京伟思医疗科技股份有限公司，成立于2001年，位于南京市，是一家以从 事医药制 ...

（文章来源：每日经济新闻） 每经AI快讯，8月13日，医疗设备板块短线走低，麦澜德跌超7%，翔宇医疗、澳华内镜、鹿得医疗、伟 思医疗等跟跌。 ...